Ativo Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Ativo Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,912	Closed	-$1.13M	–	112
2022 Q2	$1.13M	Buy	1,912 +6	+0.3%	+$3.9K	0.76%	67
2022 Q1	$1.33M	Buy	+1,906	New	+$1.21M	0.68%	80
2020 Q4	–	Sell	-402	Closed	-$225K	–	127
2020 Q3	$225K	Buy	+402	New	+$244K	0.11%	113

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ativo Capital Management's REGN Position: Q3 2022 in Review

Ativo Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 1,912 shares — an estimated $1.13M sold.

Ativo Capital Management first reported a position in REGN in Q3 2020 and held it in 3 quarters. The position peaked at $1.33M in Q1 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Ativo Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Ativo Capital Management sold 1,912 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $1.13M.
Ativo Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 3 quarters.
Ativo Capital Management's Regeneron Pharmaceuticals position peaked at $1.33M in Q1 2022.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Ativo Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.